290 related articles for article (PubMed ID: 28625652)
1. Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.
Gion M; Remon J; Caramella C; Soria JC; Besse B
Lung Cancer; 2017 Jun; 108():72-74. PubMed ID: 28625652
[TBL] [Abstract][Full Text] [Related]
2. Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases.
Dudnik E; Yust-Katz S; Nechushtan H; Goldstein DA; Zer A; Flex D; Siegal T; Peled N
Lung Cancer; 2016 Aug; 98():114-117. PubMed ID: 27393516
[TBL] [Abstract][Full Text] [Related]
3. Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment.
Kimura H; Sone T; Murata A; Koba H; Tambo Y; Hara J; Abo M; Kasahara K
Lung Cancer; 2017 Jun; 108():7-8. PubMed ID: 28625651
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis and Treatment of Leptomeningeal Metastasis in Non-small Cell Lung Cancer].
Xu Y; Li L; Wang M
Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):626-32. PubMed ID: 26483335
[TBL] [Abstract][Full Text] [Related]
5. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
Ruiz-Bañobre J; Pérez-Pampín E; García-González J; Gómez-Caamaño A; Barón-Duarte FJ; López-López R; Vázquez-Rivera F
Lung Cancer; 2017 Jun; 108():217-221. PubMed ID: 28625638
[TBL] [Abstract][Full Text] [Related]
6. Onartuzumab ineffective in non-small-cell lung cancer.
Brower V
Lancet Oncol; 2017 Feb; 18(2):e66. PubMed ID: 28017663
[No Abstract] [Full Text] [Related]
7. Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.
Sakata Y; Kawamura K; Shingu N; Ichikado K
Lung Cancer; 2016 Sep; 99():120-2. PubMed ID: 27565925
[TBL] [Abstract][Full Text] [Related]
8. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
[TBL] [Abstract][Full Text] [Related]
9. Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab.
Tabchi S; Weng X; Blais N
Lung Cancer; 2016 Sep; 99():123-6. PubMed ID: 27565926
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of Clinicopathological Feature and Prognosis for
Leptomeningeal Metastasis in Non-small Cell Lung Cancer].
Zhu M; Ren Y; Liu Y; Ban C; Gu H; Wang Z; Zhang Y
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):533-8. PubMed ID: 27561804
[TBL] [Abstract][Full Text] [Related]
11. The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
Metro G; Ricciuti B; Brambilla M; Baglivo S; Soli I; Minenza E; Leonardi GC; D'arpino A; Colabrese D; Tazza M; Zicari D; Minotti V; Chiari R
Expert Opin Drug Saf; 2017 Jan; 16(1):101-109. PubMed ID: 27910704
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab in advanced non-small-cell lung cancer.
Brower V
Lancet Oncol; 2017 Aug; 18(8):e434. PubMed ID: 28648559
[No Abstract] [Full Text] [Related]
13. Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung.
Semper H; Muehlberg F; Schulz-Menger J; Allewelt M; Grohé C
Lung Cancer; 2016 Sep; 99():117-9. PubMed ID: 27565924
[TBL] [Abstract][Full Text] [Related]
14. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report.
Ikeuchi K; Okuma Y; Tabata T
Lung Cancer; 2016 Sep; 99():148-50. PubMed ID: 27565931
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab (Tecentriq) for bladder cancer and NSCLC.
Med Lett Drugs Ther; 2017 Feb; 59(1515):e40-e41. PubMed ID: 28222066
[No Abstract] [Full Text] [Related]
16. Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression.
Takeshita M; Anai S; Mishima S; Inoue K
Ann Oncol; 2017 Jan; 28(1):186-189. PubMed ID: 28043982
[No Abstract] [Full Text] [Related]
17. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
[TBL] [Abstract][Full Text] [Related]
19. Nimotuzumab treatment and outcome analysis in patients with leptomeningeal metastasis from nonsmall cell lung cancer.
Ju Y; Wang J; Sun S; Jiao S
J Cancer Res Ther; 2016 Dec; 12(Supplement):C181-C185. PubMed ID: 28230014
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
Umemura S; Tsubouchi K; Yoshioka H; Hotta K; Takigawa N; Fujiwara K; Horita N; Segawa Y; Hamada N; Takata I; Yamane H; Kamei H; Kiura K; Tanimoto M
Lung Cancer; 2012 Jul; 77(1):134-9. PubMed ID: 22487432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
